LSE:GSK
LSE:GSKPharmaceuticals

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

Recently, GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement likely supported the company's 14% share price increase last month, alongside positive movements such as the FDA's review of linerixibat and early success in Tebipenem HBr trials. These advancements contrast the broader market, which experienced turbulence amid geopolitical tensions and surging oil...
NYSE:EQR
NYSE:EQRResidential REITs

Equity Residential (NYSE:EQR) Declares US$1 Preferred And US$1 Common Dividends For Q2

Equity Residential (NYSE:EQR) recently announced dividends on both its preferred and common shares, maintaining its strategy of shareholder returns. This announcement might have provided investors with confidence, reflected in the company's 2.5% share price increase last week, despite global market challenges like the Dow's 500-point drop following rising geopolitical tensions. With the market climbing 1.6% in the last 7 days, Equity Residential's performance aligned well, as investors...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

T. Rowe Price Group (NasdaqGS:TROW) Expands ETF Offerings With Three New Sector-Focused Funds

T. Rowe Price Group (NasdaqGS:TROW) recently launched three active transparent equity ETFs on NASDAQ, enhancing their investment product suite. Over the last quarter, the company's stock price experienced a 1.66% increase. This performance aligns with broader market movements, suggesting the ETFs might have added weight to these trends. Despite global market volatility, such as the Israel-Iran conflict impacting indices like the Dow Jones, TROW's moves remain relatively steady. Other company...